{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:12Z","timestamp":1791414132618,"version":"4.3.3"},"reference-count":9,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,12]]},"abstract":"ABSTRACT<\/jats:title>\n \n The\n in vitro<\/jats:italic>\n activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of\n Chlamydia trachomatis<\/jats:named-content>\n and\n Chlamydia pneumoniae<\/jats:named-content>\n were tested. For AZD0914, the MIC\n 90<\/jats:sub>\n s for\n C. trachomatis<\/jats:named-content>\n and\n C. pneumoniae<\/jats:named-content>\n were 0.25 \u03bcg\/ml (range, 0.06 to 0.5 \u03bcg\/ml) and 1 \u03bcg\/ml (range, 0.25 to 1 \u03bcg\/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC\n 90<\/jats:sub>\n s) were 0.5 \u03bcg\/ml for\n C. trachomatis<\/jats:named-content>\n (range, 0.125 to 1 \u03bcg\/ml) and 2 \u03bcg\/ml for\n C. pneumoniae<\/jats:named-content>\n (range, 0.5 to 2 \u03bcg\/ml).\n <\/jats:p>","DOI":"10.1128\/aac.03920-14","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T07:44:04Z","timestamp":1412667844000},"page":"7595-7596","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["In Vitro<\/i>\n Activity of AZD0914, a Novel DNA Gyrase Inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae"],"prefix":"10.1128","volume":"58","author":[{"given":"Stephan A.","family":"Kohlhoff","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"Infection iMed, AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Hammerschlag","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","volume-title":"Sexually transmitted disease surveillance 2011","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. 2012. Sexually transmitted disease surveillance 2011. U.S. Department of Health and Human Services, Atlanta, GA. http:\/\/www.cdc.gov\/std\/stats11\/surv2011.pdf."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-06839-3.00182-X"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-06839-3.00035-7"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03090-14"},{"key":"e_1_3_1_6_2","volume-title":"Abstr. 53rd Annu. Intersci. Conf. Antimicrob. Agents Chemother.","author":"Huband MD","year":"2013","unstructured":"HubandMDOttersonLGDoigPCGiacobbeRAPateySAGowravaramMBasarabGSMuellerJP. 2013. Benzisoxazoles: in vitro activity of new bacterial DNA gyrase\/topoisomerase IV inhibitors against Gram-positive, fastidious Gram-negative, atypical, and anaerobic bacterial isolates, poster F-1220. Abstr. 53rd Annu. Intersci. Conf. Antimicrob. Agents Chemother., Denver, CO, 10 to 13 September 2013."},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.30.8.1968-1971.1992"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199506000-00002"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.658776"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.194"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03920-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03920-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:46:03Z","timestamp":1645483563000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03920-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1128\/AAC.03920-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03920-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"2014-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}